Eloxx Pharmaceuticals, Inc.

ELOX | $0.9625 -51.57% 93K

(0.0% 1d) (9.7% 1m) (-85.3% 1y) (0.0% 2d) (0.0% 3d) (0.7% 7d) (100.97% volume)
Earnings Calendar: 2022-11-09
Market Cap: $ 3,025,513
http://www.eloxxpharma.com
Sec Filling | Patents | 29 employees

(US) Eloxx Pharmaceuticals, Inc. engages in the development of novel ribonucleic acid modulating drug candidates. The firm focuses on the the formulation of medicines to treat rare and ultra-rare premature stop codon diseases. It operates through the United States and Israel geographical segments. Its product includes ELX-02, a small molecule drug designed to restore production of full-length functional proteins which treats cystic fibrosis and cystinosis. The company was founded by Silvia Noiman on December 19, 2017 and is headquartered in Waltham, MA.

israel fibrosis molecule drugs

add to watch list Paper trade email alert is off

Press-releases

Eloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program Updates
Published: 2024-04-16 (Crawled : 12:00) - globenewswire.com
ELOX | $0.9625 -51.57% 93K

Health Technology

| -4.09% | O: 2.04% H: 0.0% C: -1.27%
elx-02 zkn-013 pharmaceuticals program

Delisting of Securities of Latch, Inc.; Eloxx Pharmaceuticals, Inc.; Collective Audience, Inc. (f.k.a., ABRIC SPAC I); SeqLL Inc.; Nemaura Medical Inc.; LumiraDx Limited; Cemtrex Inc.; COMSovereign Holding Corp.; Global System Dynamics; Arrival; Nubia Brand International Corp.; The Alkaline Water Company Inc.; DMK Pharmaceuticals Corporation; MedAvail Holdings, Inc.; InVivo Therapeutics Holdings Corp.; and ADDvantage Technologies Group, Inc. from The Nasdaq Stock Market
Published: 2024-03-20 (Crawled : 20:00) - globenewswire.com
COMS | $0.2001 37.35% 3.9K

Manufacturing

| 13.25% | O: -2.27% H: 27.46% C: 15.87%
WTER | $0.0016 14185.71% 2.6K

Consumer Non-Durables

| 614.29% | O: 0.0% H: 614.29% C: 0.0%
NDAQ | $60.075 0.11% 0.11% 2.3M

Finance

| -1.43% | O: 0.46% H: 3.09% C: 1.11%
CETX | $3.0301 -3.56% 900

Electronic Technology

| -28.73% | O: 0.22% H: 1.85% C: -2.22%
water company international spac pharmaceuticals global system medical therapeutics market

Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseases
Published: 2024-03-13 (Crawled : 16:00) - globenewswire.com
ELOX | $0.9625 -51.57% 93K

Health Technology

| Email alert Add to watchlist
zkn-013 rare license pharmaceuticals dermatological agreement

Eloxx Pharmaceuticals Reports Third Quarter 2023 Financial and Operating Results and Provides Business Update
Published: 2023-11-13 (Crawled : 21:00) - globenewswire.com
ELOX | $0.9625 -51.57% 93K

Health Technology

| Email alert Add to watchlist
business update pharmaceuticals financial results

Emerging Market Trends in Muscular Dystrophy: A DelveInsight Analysis of Becker Muscular Dystrophy, Myotonic Dystrophy, Facioscapulohumeral Muscular Dystrophy, and Limb-girdle Muscular Dystrophy
Published: 2023-11-06 (Crawled : 22:00) - prnewswire.com
SRPT | $116.59 -1.1% -1.12% 500K

Health Technology

| 47.18% | O: 0.65% H: 4.43% C: 2.87%
RNA | $23.04 -2.17% -2.21% 1.1M

Health Technology

| 344.34% | O: -0.57% H: 10.72% C: 10.63%
trends market

Eloxx Pharmaceuticals Reports Additional Confirmation that All Nonsense Mutation Alport Syndrome Patients Treated with ELX-02 in Phase 2 Study had Improvement in Kidney Morphology and Clinical Benefit of Reduction or Stabilization of Proteinuria
Published: 2023-10-09 (Crawled : 12:00) - globenewswire.com
ELOX | $0.9625 -51.57% 93K

Health Technology

| -78.24% | O: -0.46% H: 4.19% C: 2.33%
elx-02 kidney pharmaceuticals study

Eloxx Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Published: 2023-09-19 (Crawled : 12:00) - globenewswire.com
ELOX | $0.9625 -51.57% 93K

Health Technology

| -82.78% | O: -0.18% H: 1.83% C: 1.83%
nasdaq direct offering pharmaceuticals

Eloxx Pharmaceuticals Reports Independent Confirmation of Positive Biopsy Results in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome
Published: 2023-09-18 (Crawled : 11:00) - globenewswire.com
ELOX | $0.9625 -51.57% 93K

Health Technology

| -84.01% | O: 1.87% H: 0.0% C: -8.85%
elx-02 positive pharmaceuticals results study

Eloxx Pharmaceuticals Provides Program Updates on ELX-02 and ZKN-013
Published: 2023-09-07 (Crawled : 13:00) - globenewswire.com
ELOX | $0.9625 -51.57% 93K

Health Technology